Welcome to ViiV Exchange UK

Welcome to
ViiV Exchange UK

Here until HIV and AIDS are not.

Read more

ViiV HEALTHCARE'S MEDICINES AND CLINLCAL RESOURCES

The ViiV Exchange is an online portal designed to help the UK healthcare professional access the latest information on our medicines and clinical resources.

Browse Dovato resources

 

DOVATO (Dolutegravir/lamivudine)

DOVATO (Dolutegravir / lamivudine)

Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Read more Prescribing information

DOVATO RESOURCES

ViiV Exchange Videos
Resources

Videos

Watch experts in HIV share the details of Dovato studies and watch internal and external experts share their opinions on the latest data.

View videos

ViiV Exchange Slide Sets
Resources

Slide Sets

Catch up on conference symposia, webinars and meeting presentations and learn more about the latest data for Dovato.

View Slide Sets

ViiV Exchange Infographics
Resources

Infographics

Download bite-size infographics on the latest studies and data to help inform your HIV practice

View Infographics

VOCABRIA▼(Cabotegravir) + REKAMBYS▼(Rilpivirine)

Cabotegravir in combination with rilpivirine is indicated for treatment of HIV-1 in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior failure with, agents of NNRTI and INI class.

Read more Prescribing information

RUKOBIA▼(Fostemsavir)

Indicated for adults with multidrug resistant HIV-1 infection (in combination with other ARVs) for whom it is otherwise not possible to construct a suppressive antiviral regimen.

Prescribing information

DOVATO (Dolutegravir/lamivudine)

Dolutegravir (DTG)

Dolutegravir (DTG) has been studied across diverse patient populations as part of both 3-drug and 2-drug regimens, including patients who are virologically suppressed, treatment-experienced or treatment-naïve.

Read more

PM-GB-HVX-WCNT-210001 | October 2021